AllMeD Solutions

Building Tomorrow's Minimally Invasive Cardiovascular Solutions

TASE: ALMD | Company Overview | April, 2026

AllMeD Solutions

Pioneering Minimally Invasive Medicine Since 2004

Vision & Mission

Our Vision

To build a strong, leading medical device company specializing in minimally invasive technologies and products, with a focus on the cardiovascular field.

Cardiovascular Focus

Deep expertise in transcatheter valve and embolic protection technologies

R&D Excellence

Synergistic R&D investments driving a broad portfolio of minimally invasive innovations

Value Creation

Develop, validate, and exit or commercialize subsidiaries through strategic partnerships or M&A

Strategy: Build → Validate → Commercialize or Exit | Structured as a holding company of breakthrough cardiovascular medtech subsidiaries

Management Team

Prof. Oz Shapira

CEO, AllMeD | Chairman, TruLeaf

Emeritus Professor of Cardiothoracic Surgery, Hebrew University Faculty of Medicine, Jerusalem, Israel. Physician-researcher, Hadassah Ein Kerem Hospital. MD, Hebrew University. Former Full Professor and Clinical Director of Cardiothoracic Surgery, Boston University Medical Center, Boston, MA, USA. CEO since March 2022.

Ifat Gabay, CPA

CFO & VP Finance & IT

CPA. BSc Economics & Accounting, Ruppin Academic Center. MBA, Tel Aviv University. CFO since September 2024. Oversees group finance and information systems.

Benjamin Spenser

Co-Founder & CEO, TruLeaf Medical Ltd.

BSc Mechanical Engineering, Technion, Haifa. MBA, Swinburne University (Australia). Together with Netanel Benichou, co-developed the Sapien3 (TAVR). Founder of Gardia Medical and MTRE.

Netanel Benichou

Co-Founder & CTO, TruLeaf Medical Ltd.

MSc Mechanical Engineering, Technion, Haifa. Together with Benjamin Spenser, co-developed the Sapien3 (TAVR). Co-inventor of RoseDoc. Chief Technology Officer leading design and engineering of the two-stage transcatheter valve system.

Board of Directors

Dr. David Milch

Chairman of the Board

—

US-born medtech investor & advisor. Active Chairman since Sept 2011. B.Sc. Stanford; MD Harvard. Boards: TruLeaf, IBI, ProCatid. New York.

Ind.

Ofer Tismchi, CPA

External Director

Chair – Audit
Member – Compensation

CPA; Economics & Agri., Hebrew Univ. Partner, Dover Group. Redhill Biopharma, Maavar Products, Kanamore Biotex. Appointed Aug 2025. Financial Expert.

Ind.

Dr. Yehudit Zilberstein

External Director

Chair – Compensation
Member – Audit

BSc/MSc/PhD Weizmann. CEO Alon Medtech Ventures. Director in 13 portfolio companies. Appointed Aug 2022.

Prof. Dan Galai

Director

Member – Audit
Member – Compensation

DBA, Univ. of Chicago. Professor, Hebrew University. Co-developer of Black-Scholes model. Joined June 2025. Financial Expert.

Yehudit Gal

Director

—

VP Strategy & Business Dev., HM Medical Solution. M&A, Mgmt. Centre Europe. Mentor MBA, Technion. Founded Medonna NGO.

Active Subsidiaries

Two active R&D subsidiaries, both focused on the cardiovascular space

TruLeaf Medical Ltd.

Transcatheter Heart Valve Replacement

- RoseDoc system: Mitral & Tricuspid valve replacement via transcatheter
- FIH study ONGOING in India — 4 patients enrolled, targeting 10 total (Tricuspid, 2025–2026)
- Helsinki approval: Uzbekistan, South Africa & additional sites
- 7× IIA grants received; NIS 1.4M grant approved Dec 2025
- Target valuation: $400–500M at exit

Owned: 100% (68.5% fully diluted)

ProCatid Medical Ltd.

Embolic Protection Device (UniGrd System)

- UniGrd (formerly WIRION): filter for carotid artery catheterization
- Holds exclusive worldwide perpetual license for Carotid EPD
- FDA & TGA-approved for carotid indication + carotid stent
- Sold IP/inventory to CSI (now Abbott); retains Carotid rights
- Continuing IP maintenance; evaluating re-commercialization

Owned: 100% (fully diluted)

TruLeaf Medical Ltd.

Team | Technology | Innovation

Core Team

Benjamin Spenser

Co-Founder & CEO

BSc Mechanical Eng., Technion. MBA, Swinburne Univ. (Australia). Together with Netanel Benichou, co-developed the first-ever transcatheter aortic valve — the Sapien3 (TAVR). Co-inventor of RoseDoc. TruLeaf CEO since 2019.

Netanel Benichou

Co-Founder & CTO

Together with Benjamin Spenser, co-developed the first-ever transcatheter aortic valve — the Sapien3 (TAVR). Co-inventor of RoseDoc. Chief Technology Officer leading design and engineering of the two-stage transcatheter valve system.

R&D Team (14 members)

Engineering & Clinical Operations

Multidisciplinary team: mechanical engineering, biomedical device design, materials science, and clinical trial operations.

Prof. Oz Shapira

Chairman — TruLeaf Board

Emeritus Professor of Cardiothoracic Surgery, Hebrew University. Strategic clinical guidance, KOL network, and regulatory advisory.

RoseDoc Technology Platform

Two-Stage Transcatheter System

Step 1: Docking Station implanted in the atrium. Step 2: Biological valve deployed into the docking station. Both steps fully percutaneous — needle puncture only, no open surgery.

Unique Docking Station

Proprietary anchor placed in the left (Mitral) or right (Tricuspid) atrium. Secures the valve and compensates for annular anatomy variability.

Single Valve for Two Indications

RoseDoc is the only system designed for both Mitral and Tricuspid valve replacement — compatible with any balloon-expandable biological valve.

Patent Portfolio

Multiple patents registered globally. Co-invented by Benjamin Spenser and Netanel Benichou.

First-in-Human (FIH) Trials

Clinical program advancing — first human transcatheter valve implantations achieved; trial ongoing

Jan 2023	Georgia - Helsinki ethics approval. Initial planned site, discontinued due to a national policy change.
Jul 2024	Uzbekistan - Helsinki approval. PI – Dr. Horst Sievert - world-renowned interventional cardiologist.
Sep 2025	India, Step 1 (Docking Station): First-ever implantation of the Docking Device in 2 patients with TR — compassionate use framework.
Dec 2025	India, step 2 (Valve): valve deployment in the 1st 2 patients. Two additional Step-1 patients enrolled. Four total enrolled, targeting 10.
Dec 2025	South Africa - Helsinki approval — South Africa TMVR site. PI - Prof. Farrel Hellig – world-renowned interventional cardiologist.
2026	ONGOING: India – FIH remaining 6 patients, Uzbekistan – TTVR, South Africa – TMVR. Expansion to Brazil, Israel.

India FIH ONGOING — 4 patients enrolled (Step 1 & 2 completed in 2), targeting 10 total. First complete transcatheter valve replacements in humans ever performed with RoseDoc.

TruLeaf Value-Creating Milestones

Strategic milestones from FIH completion to pivotal trial and commercial exit

2025

First 2 TTVRs
Tricuspid FIH India (5 pt.)
Device Verification Testing

2026

Completion of FIH in India (10 Pt.)
Tricuspid FIH Uzbekistan (5-10 Pt.)
Mitral FIH South Africa (5 pt.)
Device Verification Testing (cont.)
Funding: $8M

2027

2nd Human Trial start
Tricuspid 2nd study (40 pt.)
Preparation for Pivotal Trial
Device Verification Testing (cont.)
Funding: $12M

2028

Pivotal Trial
Completion of 2nd Human Trial
Funding: $50M
Target Valuation: $400–500M

Target Exit
$400–500M

TruLeaf received 7 consecutive grants from the Israel Innovation Authority (IIA) for a total of ~ US$ 3.4M.

RoseDoc System – Two-Step Procedure

Minimally invasive transcatheter valve replacement — no open-heart surgery

1 Docking Station Implantation

A proprietary Docking Station (anchor) is implanted percutaneously via catheter (needle puncture only) into the left atrium (Mitral) or right atrium (Tricuspid). No open-heart surgery. The Docking Station adapts to the patient's anatomy and provides a stable platform for the valve.

2 Biological Valve Deployment

In a separate procedure, a biological prosthetic valve is delivered via catheter and deployed directly into the Docking Station. The valve fits both Mitral and Tricuspid positions with no open surgery required.

Key Unique Advantages of RoseDoc

1) The only device that fits both Mitral and Tricuspid valves
2) Anchoring device compatible with any balloon-expandable valve
3) Simple, fast and reproducible procedure
4) Strong natural tissue-response-based anchoring
5) Fully retrievable anchoring device
6) Minimal risk for LVOT obstruction in TMVR
7) Minimal risk for A-V Block in TTVR

Market Opportunity & Funding

Massive unmet global need — 40–50 million patients with no adequate treatment option

40–50M

Patients worldwide with untreated Mitral or Tricuspid valve regurgitation

$30–40B

Estimated addressable global market for transcatheter valve replacement

$400–500M

TruLeaf target company valuation at exit / pivotal trial milestone

IIA (Israel Innovation Authority) Grants Received — TruLeaf (2017–2025, 7 rounds)

Grant Round 7 (Latest)
Approved: December 2025 | Amount: ~ US 460K (NIS 1.4M) | Period: 12 months from September 2025

Investment & Capital Strategy

- Seven IIA grants (2017–2025) provide a total of ~US 3.4M (NIS 11.4 M) non-dilutive R&D funding
- Company plans further capital raises via TruLeaf share issuances, strategic partners, and potential IPO

ProCatid Medical Ltd.

UniGrd Embolic Protection System — FDA & TGA Approved for Carotid Artery Procedures

UniGrd System Technology

Embolic Protection Device (EPD)

Unique filter system designed to capture blood clots, particles, and emboli generated during catheterization procedures including carotid artery stenting.

Over-the-Wire Unique Design

Key differentiator: the UniGrd can be inserted over any guidewire per the operator's preference. That same guidewire can then be used directly for stent deployment — eliminating wire exchange and re-crossing the lesion, simplifying the procedure and minimizing procedural risk.

Carotid Artery Indication

Exclusively approved for carotid artery stenting (CAS) — the high-risk catheter procedure for stroke prevention. Arteries 3.5–6.0mm in diameter.

Collection Catheter

Retrieval catheter collapses the filter after the procedure, capturing all emboli before removal.

Regulatory Approvals Retained

ProCatid retains FDA (USA) and TGA (Australia) approvals for the Carotid indication with Carotid stent.

Current Status

- ✅ FDA-approved (USA) for carotid indication
- ✅ CE Mark approved — European Union
- ✅ TGA-approved — Australia / New Zealand
- 🔄 2019: Sold IP, inventory & non-carotid rights to CSI (now Abbott)
- 🔒 Retains exclusive perpetual worldwide license for Carotid use
- ⏸ No active manufacturing or distribution as at report date
- 🔍 Evaluating re-commercialization strategies

ProCatid – Assets & Strategic Position

Retaining high-value regulatory approvals while evaluating next steps for the UniGrd carotid platform

Regulatory Assets (Retained)

- FDA 510(k) clearance for UniGrd Carotid EPD
- TGA approval (Australia / New Zealand)
- Exclusive worldwide license — perpetual, royalty-free
- Rights cover Carotid indication + carotid stent use only

IP & Technology Position

- Sold patents transferred to CSI/Abbott
- Retains exclusive license rights over Carotid IP
- Unique one-size filter design proprietary know-how
- Continuing R&D expertise on catheter-based EPD

Commercial Pathway Options

- Re-launch manufacturing for carotid EPD
- License Carotid rights to strategic partner
- Co-development agreement with device OEM
- Explore regulatory expansion beyond Carotid

CSI (acquired by Abbott, 2023) holds the main IP; ProCatid retains strategic Carotid-specific rights — a beachhead for potential re-entry into the EPD market.

Prior Successful Subsidiaries

AllMeD's track record: building and successfully exiting breakthrough medtech ventures

Allium Medical

Gastrointestinal & Urological Stents

Technology: Proprietary fully-covered nitinol stents — primarily for urological applications (ureter, urethra, prostate) and biliary/GI indications

Achievements: CE Mark & FDA clearances. International commercial sales.

Exit: Successfully sold to **Dalhausen GmbH**

SUCCESSFUL EXIT ✓

Gardia Medical

(now: ProCatid / UniGrd system)

Technology: WIRION embolic protection system — unique over-the-wire design avoids wire exchange and re-crossing the stenosis lesion

Achievements: FDA 510(k) clearance. CE Mark (EU). TGA approval (Australia). Successful commercialization.

Exit: IP and assets sold to **Cardiovascular Systems Inc (CSI)** — later acquired by Abbott Laboratories (April 2023)

SUCCESSFUL EXIT ✓

Allium Medical

GI & Urological Nitinol Stents | Sold to Dalhausen GmbH, Germany

Core Focus — Urological Stents

- Primarily urological stents: ureter, urethra, and prostatic applications
- Treatment of malignant & benign urological strictures and obstructions
- Also covers biliary and GI indications (duodenal, colorectal)
- Minimally invasive endoscopic deployment — no open surgery

Technology

- Proprietary fully-covered nitinol stents — unique alloy properties
- Patented anti-migration design for long-term stable placement
- Custom-engineered delivery systems for urological anatomy
- Multiple stent configurations for different anatomical sites

Regulatory & Commercial

- CE Mark approval (Europe)
- FDA 510(k) clearance (United States)
- International commercial sales — multiple markets
- Established global distribution and clinical network

Exit — Dalhausen GmbH, Germany

- Acquired by Dalhausen, leading German surgical medtech company
- Dalhausen founded 1912; broad surgical products portfolio
- Validated AllMeD's Build-Develop-Exit medtech model
- Freed AllMeD capital to invest in cardiovascular pipeline

Gardia Medical (now ProCatid Medical)

WIRION Embolic Protection Device | Sold to Cardiovascular Systems Inc. (CSI) → Abbott

Clinical Problem Solved

- Emboli (clots, particles) released during catheterization cause stroke and MI
- Carotid artery stenting (CAS) carries high embolic risk to the brain
- Standard EPDs require wire exchange — adding complexity and stroke risk
- WIRION eliminated wire exchange: unique over-the-wire compatibility

Key Technological Advantage

- Inserted OVER any standard guidewire — no need to replace the wire
- Avoids re-crossing the stenotic lesion: reduces procedural risk and time
- One-size filter fits arteries 3.5–6.0mm — universal compatibility
- Fully collapsible collection catheter captures all emboli on retrieval

Regulatory Achievements

- FDA 510(k) clearance — USA (2015)
- CE Mark approval — European Union
- TGA approval — Australia & New Zealand (2016)
- Approved for carotid stenting indication with carotid stent

Exit to CSI / Abbott

- IP, inventory, equipment sold to Cardiovascular Systems Inc. (CSI, 2019)
- CSI subsequently acquired by Abbott Laboratories (April 2023)
- ProCatid retained exclusive perpetual license for Carotid rights
- Exemplifies AllMeD's proven Build-Validate-Exit strategy

Financial Summary – FY 2025

Based on audited consolidated financial statements for year ended December 31, 2025

NIS 28.1M

Total Equity (Dec 31, 2025)

Shareholders' equity, consolidated

NIS 27.4M

Working Capital

Positive working capital position

R&D Focus

Revenue Stage

Pre-revenue; all products in development

Team (Dec 2025)

Category	FY2025	Report Date
Senior Mgmt / Finance / Admin	4	4
R&D Personnel	15	16
Permanent Consultants	4	4
Total	22	23

Funding Approach

- Primary: Equity raises at parent and subsidiary level
- IIA non-dilutive innovation grants (NIS 1.4M — Dec 2025)
- $500K PIPE transaction completed January 2026
- Deposit interest income contributes to cash offset
- No debt financing; no dividend policy

AllMeD Solutions

Building the Future of Minimally Invasive Cardiovascular Medicine

Contact & IR: Prof. Oz Shapira, CEO | Ifat Gabay, CFO | AllMeD Solutions Ltd.

TASE Ticker: ALMD | Incorporated: Israel, 2004 | Auditor: Kost Forer Gabbay & Kasierer (EY Israel)

Email info@almd-solutions.com | Tel +972 74 765 0353 | Web https://www.almd-solutions.com | Address 12 Ha-Ilan Street, Or Akiva, POB 174, 3063908, Israel

AllMeD Solutions